Recent Advances in the Understanding and Treatment of Pediatric Leukemias

Advances in Pediatrics

Volumn 59, Issue 1, 2012, Pages 329-358

  Maloney, Kelly W ^a   Giller, Roger ^a   Hunger, Stephen P ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Hematopoietic; Pediatric leukemia; Stem cell transplant; Treatment

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; CHILD; CHRONIC MYELOID LEUKEMIA; DRUG CONTRAINDICATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; METHODOLOGY; MOLECULARLY TARGETED THERAPY; REVIEW;

ADOLESCENT; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; YOUNG ADULT;

EID: 84863813301     PISSN: 00653101     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yapd.2012.04.010     Document Type: Review

References (124)

1. Linet M.S., Ries L.A., Smith M.A., et al. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 1999, 91(12):1051-1058.
2. Smith M.A., Seibel N.L., Altekruse S.F., et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 2010, 28(15):2625-2634.
3. Pulte D., Gondos A., Brenner H. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004. J Natl Cancer Inst 2008, 100(18):1301-1309.
4. Pulte D., Gondos A., Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood 2009, 113(7):1408-1411.
5. Pulte D., Gondos A., Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica 2008, 93(4):594-600.
6. Hunger S.P., Lu X., Devidas M., et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 2012, 30(14):1663-1669.
7. Conter V., Arico M., Basso G., et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010, 24(2):255-264.
8. Moricke A., Zimmermann M., Reiter A., et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010, 24(2):265-284.
9. Gaynon P.S., Angiolillo A.L., Carroll W.L., et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group report. Leukemia 2010, 24(2):285-297.
10. Salzer W.L., Devidas M., Carroll W.L., et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the Children's Oncology Group. Leukemia 2010, 24(2):355-370.
11. Silverman L.B., Stevenson K.E., O'Brien J.E., et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010, 24(2):320-334.
12. Pui C.H., Pei D., Sandlund J.T., et al. Long-term results of St Jude total therapy studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010, 24(2):371-382.
13. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371(9617):1030-1043.
14. Bostrom B.C., Sensel M.R., Sather H.N., et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003, 101(10):3809-3817.
15. Mitchell C.D., Richards S.M., Kinsey S.E., et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005, 129(6):734-745.
16. Teuffel O., Kuster S.P., Hunger S.P., et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia 2011, 25(8):1232-1238.
17. Winick N.J., Salzer W.L., Devidas M., et al. Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high-risk acute lymphoblastic leukemia (HR-ALL): a report from the Children's Oncology Group study AALL0232. J Clin Oncol 2011, 29(Suppl 15):9504.
18. Silverman L.B., Supko J.G., Stevenson K.E., et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood 2010, 115(7):1351-1353.
19. Pieters R., Hunger S.P., Boos J., et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011, 117(2):238-249.
20. Aur R.J., Simone J.V., Hustu H.O., et al. A comparative study of central nervous system irradiation and intensive chemotherapy early in remission of childhood acute lymphocytic leukemia. Cancer 1972, 29(2):381-391.
21. Pui C.H., Howard S.C. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008, 9(3):257-268.
22. Pui C.H., Campana D., Pei D., et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009, 360(26):2730-2741.
23. Veerman A.J., Kaspers G.J. Towards individualised treatment in childhood leukaemia. Lancet Oncol 2010, 11(6):502-503.
24. Larsen E.C., Salzer W.L., Devidas M. Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): a report from the Children's Oncology Group study AALL0232. J Clin Oncol 2011, 29(Suppl 15):3.
25. Schrappe M. Evolution of BFM trials for childhood ALL. Ann Hematol 2004, 83(Suppl 1):S121-S123.
26. Seibel N.L., Steinherz P.G., Sather H.N., et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008, 111(5):2548-2555.
27. Matloub Y., Bostrom B.C., Hunger S.P., et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011, 118(2):243-251.
28. Conter V., Valsecchi M.G., Silvestri D., et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 2007, 369(9556):123-131.
29. Berg S.L., Blaney S.M., Devidas M., et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005, 23(15):3376-3382.
30. Kurtzberg J., Ernst T.J., Keating M.J., et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005, 23(15):3396-3403.
31. Dunsmore K.D.M., Borowitz M.J., Winick N., et al. Nelarabine in combination with intensive modified BFM AALL00P2: a pilot study for the treatment of high risk T-ALL a report from the Children's Oncology Group. JCO 2008, 26(15S):10002.
32. Coustan-Smith E., Mullighan C.G., Onciu M., et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009, 10(2):147-156.
33. Arico M., Valsecchi M.G., Camitta B., et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000, 342(14):998-1006.
34. Arico M., Schrappe M., Hunger S.P., et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 2010, 28(31):4755-4761.
35. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344(14):1031-1037.
36. Schultz K.R., Bowman W.P., Aledo A., et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009, 27(31):5175-5181.
37. Hunger S.P., Raetz E.A., Loh M.L., et al. Improving outcomes for high-risk ALL: translating new discoveries into clinical care. Pediatr Blood Cancer 2011, 56(6):984-993.
38. Rubnitz J.E., Link M.P., Shuster J.J., et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1994, 84(2):570-573.
39. Mann G., Attarbaschi A., Schrappe M., et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood 2010, 116(15):2644-2650.
40. Pieters R., Schrappe M., De Lorenzo P., et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007, 370(9583):240-250.
41. Dreyer Z.E., Dinndorf P.A., Camitta B., et al. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. J Clin Oncol 2011, 29(2):214-222.
42. Brown P., Levis M., Shurtleff S., et al. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 2005, 105(2):812-820.
43. Schafer E.S., Hunger S.P. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol 2011, 8(7):417-424.
44. Stock W., La M., Sanford B., et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008, 112(5):1646-1654.
45. Nachman J.B., La M.K., Hunger S.P., et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol 2009, 27(31):5189-5194.
46. Nguyen K., Devidas M., Cheng S.C., et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 2008, 22(12):2142-2150.
47. Raetz E.A., Borowitz M.J., Devidas M., et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group study [corrected]. J Clin Oncol 2008, 26(24):3971-3978.
48. Schultz K.R., Pullen D.J., Sather H.N., et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007, 109(3):926-935.
49. Harrison C.J. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol 2009, 144(2):147-156.
50. Nachman J.B., Heerema N.A., Sather H., et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007, 110(4):1112-1115.
51. Mullighan C.G., Downing J.R. Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. Leukemia 2009, 23(7):1209-1218.
52. Mullighan C.G., Su X., Zhang J., et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009, 360(5):470-480.
53. Mullighan C.G., Zhang J., Harvey R.C., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2009, 106(23):9414-9418.
54. Harvey R.C., Mullighan C.G., Chen I.M., et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010, 115(26):5312-5321.
55. Verstovsek S., Kantarjian H., Mesa R.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010, 363(12):1117-1127.
56. Borowitz M.J., Devidas M., Hunger S.P., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008, 111(12):5477-5485.
57. Rubnitz J.E., Gibson B., Smith F.O. Acute myeloid leukemia. Hematol Oncol Clin North Am 2010, 24(1):35-63.
58. Preisler H.D., Raza A., Larson R., et al. Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: a Leukemia Intergroup pilot study. Blood 1989, 73(1):255-262.
59. Kaspers G.J., Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia 2005, 19(12):2025-2029.
60. Burnett A.K., Wheatley K., Goldstone A.H., et al. Long-term results of the MRC AML10 trial. Clin Adv Hematol Oncol 2006, 4(6):445-451.
61. Stevens R.F., Hann I.M., Wheatley K., et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998, 101(1):130-140.
62. Tsukimoto I., Tawa A., Horibe K., et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2009, 27(24):4007-4013.
63. Estey E.H. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012, 87(1):89-99.
64. Radhi M., Meshinchi S., Gamis A. Prognostic factors in pediatric acute myeloid leukemia. Curr Hematol Malig Rep 2010, 5(4):200-206.
65. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92(7):2322-2333.
66. Niewerth D., Creutzig U., Bierings M.B., et al. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 2010, 116(13):2205-2214.
67. Woods W.G., Neudorf S., Gold S., et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001, 97(1):56-62.
68. Sanz M.A., Grimwade D., Tallman M.S., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113(9):1875-1891.
69. Sanz M.A., Martin G., Rayon C., et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999, 94(9):3015-3021.
70. Fenaux P., Chevret S., Guerci A., et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia 2000, 14(8):1371-1377.
71. Sanz M.A., Martin G., Gonzalez M., et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004, 103(4):1237-1243.
72. Ravindranath Y., Gregory J., Feusner J. Treatment of acute promyelocytic leukemia in children: arsenic or ATRA. Leukemia 2004, 18(10):1576-1577.
73. Testi A.M., Biondi A., Lo Coco F., et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005, 106(2):447-453.
74. Sanz M.A., Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011, 29(5):495-503.
75. Zeller B., Gustafsson G., Forestier E., et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 2005, 128(6):797-804.
76. Rao A., Hills R.K., Stiller C., et al. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 2006, 132(5):576-583.
77. Ge Y., Jensen T.L., Stout M.L., et al. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res 2004, 64(2):728-735.
78. Taub J.W., Huang X., Matherly L.H., et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 1999, 94(4):1393-1400.
79. Meshinchi S., Woods W.G., Stirewalt D.L., et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001, 97(1):89-94.
80. Meshinchi S., Alonzo T.A., Stirewalt D.L., et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006, 108(12):3654-3661.
81. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98(6):1752-1759.
82. Ho P.A., Alonzo T.A., Gerbing R.B., et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2009, 113(26):6558-6566.
83. Rau R., Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 2009, 27(4):171-181.
84. Braoudaki M., Papathanassiou C., Katsibardi K., et al. The frequency of NPM1 mutations in childhood acute myeloid leukemia. J Hematol Oncol 2010, 3:41.
85. Hollink I.H., Zwaan C.M., Zimmermann M., et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 2009, 23(2):262-270.
86. Suttorp M., Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology Am Soc Hematol Educ Program 2010, 2010:368-376.
87. Heisterkamp N., Jenster G., ten Hoeve J., et al. Acute leukaemia in bcr/abl transgenic mice. Nature 1990, 344(6263):251-253.
88. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247(4944):824-830.
89. Calabretta B., Perrotti D. The biology of CML blast crisis. Blood 2004, 103(11):4010-4022.
90. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112(13):4808-4817.
91. Davies S.M., DeFor T.E., McGlave P.B., et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001, 110(5):339-346.
92. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003, 102(4):1224-1231.
93. Suttorp M., Yaniv I., Schultz K.R. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?. Biol Blood Marrow Transplant 2011, 17(Suppl 1):S115-S122.
94. Hochhaus A., O'Brien S.G., Guilhot F., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23(6):1054-1061.
95. Lombardo L.J., Lee F.Y., Chen P., et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47(27):6658-6661.
96. Kantarjian H., Shah N.P., Hochhaus A., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362(24):2260-2270.
97. Saglio G., Kim D.W., Issaragrisil S., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362(24):2251-2259.
98. Schmid H., Jaeger B.A., Lohse J., et al. Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica 2009, 94(8):1177-1179.
99. Mariani S., Giona F., Basciani S., et al. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008, 372(9633):111-112.
100. Kimoto T., Inoue M., Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol 2009, 89(2):251-252.
101. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75(3):555-562.
102. Petersdorf E.W. Risk assessment in haematopoietic stem cell transplantation: histocompatibility. Best Pract Res Clin Haematol 2007, 20(2):155-170.
103. Weisdorf D.J., Billett A.L., Hannan P., et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood 1997, 90(8):2962-2968.
104. Warlick E.D., Defor T., Blazar B.R., et al. Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18(3):480-486.
105. Ringden O.T., Le Blanc K., Remberger M. Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications. Exp Hematol 2005, 33(5):505-512.
106. Kontoyiannis D.P., Lewis R.E., Marr K. The burden of bacterial and viral infections in hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2009, 15(Suppl 1):128-133.
107. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol 2008, 143(4):455-467.
108. Ljungman P., Hakki M., Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am 2011, 25(1):151-169.
109. Ferrara J.L., Levine J.E., Reddy P., et al. Graft-versus-host disease. Lancet 2009, 373(9674):1550-1561.
110. Pulsipher M.A., Skinner R., McDonald G.B., et al. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: the need for pediatric-specific long-term follow-up guidelines. Biol Blood Marrow Transplant 2011, 18(3):334-347.
111. Schrappe M., Hunger S.P., Pui C.H., et al. Outcome after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012, 366(15):1371-1381.
112. Bunin N., Aplenc R., Kamani N., et al. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003, 32(6):543-548.
113. Oliansky D.M., Camitta B., Gaynon P., et al. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant 2012, 18(4):505-522.
114. Pulsipher M.A., Boucher K.M., Wall D., et al. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium study ONC0313. Blood 2009, 114(7):1429-1436.
115. Verneris M.R., Brunstein C.G., Barker J., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114(19):4293-4299.
116. Alyea E.P., DeAngelo D.J., Moldrem J., et al. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010, 16(8):1037-1069.
117. Carpenter P.A., Meshinchi S., Davies S.M. Transplantation for AML in children. Biol Blood Marrow Transplant 2012, 18(Suppl 1):S33-S39.
118. Oliansky D.M., Rizzo J.D., Aplan P.D., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2007, 13(1):1-25.
119. Gratwohl A., Brand R., Apperley J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006, 91(4):513-521.
120. Radich J.P., Gooley T., Bensinger W., et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003, 102(1):31-35.
121. Locatelli F., Nollke P., Zecca M., et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 2005, 105(1):410-419.
122. Niemeyer C.M., Baumann I. Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program 2011, 2011:84-89.
123. Hasle H., Baumann I., Bergstrasser E., et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004, 18(12):2008-2014.
124. Strahm B., Nollke P., Zecca M., et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia 2011, 25(3):455-462.